Patents by Inventor Erkki Ruoslahti

Erkki Ruoslahti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10500246
    Abstract: Disclosed are compositions and methods for treatment of atherosclerosis and atherosclerotic plaques. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerosis. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerotic plaques. In particular, compositions comprising a plaque-homing element, a CendR-activating element, and a plaque-inhibiting element are disclosed.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: December 10, 2019
    Assignee: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Lauri Paasonen
  • Patent number: 10370245
    Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: August 6, 2019
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara
  • Publication number: 20190134211
    Abstract: Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal.
    Type: Application
    Filed: August 7, 2018
    Publication date: May 9, 2019
    Inventors: Masanobu Komatsu, David Mann, Erkki Ruoslahti
  • Publication number: 20190022170
    Abstract: Compositions and methods useful for delivery of targeted therapies for pulmonary arterial hypertension, sepsis, cancer and cachexia. The compositions and methods are based on peptide pharmacophores that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. Peptide pharmacophores may selectively target tumor vasculature, regenerating tissue, wounded tissue, inflamed tissue, fibrotic tissue, remodeled tissue, tissue characterized by elevated heparanase levels, and have the ability to internalize into such diseased cells.
    Type: Application
    Filed: August 4, 2015
    Publication date: January 24, 2019
    Inventors: David Mann, Erkki Ruoslahti, Masanobu Komatsu
  • Publication number: 20190022239
    Abstract: Provided herein are biomolecule conjugates, and methods of use thereof, wherein the conjugate comprises a cytokine, typically an immunopotentiating cytokine, and a peptide comprising or consisting of the sequence CSGRRSSKC (SEQ ID NO:1). Biomolecule conjugates of the invention find application, inter alia, in the treatment of turnouts, atherosclerosis and fibrosis, and the degradation of ECM associated therewith. Also provided herein are uses of a peptide comprising or consisting of the sequence of SEQ ID NO:1, optionally linked to a delectable agent and/or a carrier, in the detection and/or localisation of tumour, atherosclerotic and fibrotic tissue.
    Type: Application
    Filed: January 19, 2017
    Publication date: January 24, 2019
    Applicants: The University of Western Australia, Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Juliana Binti HAMZAH, Ruth Annelore GANSS, Erkki RUOSLAHTI, Hector R. BILIRAN, Jr.
  • Patent number: 10179801
    Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences, such as truncated LyP-1 peptides, that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: January 15, 2019
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara, Lise Roth
  • Publication number: 20180303898
    Abstract: Disclosed are compositions and methods for treatment of atherosclerosis and atherosclerotic plaques. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerosis. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerotic plaques. In particular, compositions comprising a plaque-homing element, a CendR-activating element, and a plaque-inhibiting element are disclosed.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 25, 2018
    Applicant: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Lauri Paasonen
  • Publication number: 20180296696
    Abstract: Disclosed are methods and compositions for selectively targeting sites of traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain injury, shows selective binding to mouse and human brain injury lesions, and when systemically injected, specifically homes to sites of injury in penetrating and non-penetrating (controlled cortical impact) brain injury models. Also disclosed are methods and compositions for delivering therapeutic compounds to such sites. CAQK-coated nanoparticles containing silencing oligonucleotides provide an alternative to local delivery of therapeutics, which is invasive and can add complications to the injury.
    Type: Application
    Filed: September 2, 2016
    Publication date: October 18, 2018
    Applicant: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Erkki RUOSLAHTI, Aman MANN, Pablo SCODELLER, Sazid HUSSAIN
  • Publication number: 20180244720
    Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).
    Type: Application
    Filed: April 22, 2016
    Publication date: August 30, 2018
    Applicant: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Tambet Teesalu, Erkki Ruoslahti, Kazuki Sugahara, Shweta Sharma
  • Patent number: 10039838
    Abstract: Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: August 7, 2018
    Assignees: Vascular Biosciences, Sanford-Burnham Medical Research Institute
    Inventors: Masanobu Komatsu, David Mann, Erkki Ruoslahti
  • Publication number: 20170246236
    Abstract: Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Application
    Filed: December 12, 2016
    Publication date: August 31, 2017
    Inventors: Lilach Agemy, Dinorah Friedmann-Morvinski, Venkata Ramana Kotamraju, Erkki Ruoslahti, Kazuki Sugahara, Inder Verma
  • Patent number: 9581598
    Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: February 28, 2017
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Pirjo Laakkonen
  • Patent number: 9522198
    Abstract: Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to tumors, sties of injury and blood clots in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tumors, sites of injury and blood clots.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: December 20, 2016
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Jan Pilch
  • Publication number: 20160184447
    Abstract: Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal.
    Type: Application
    Filed: November 10, 2015
    Publication date: June 30, 2016
    Inventors: Masanobu Komatsu, David Mann, Erkki Ruoslahti
  • Patent number: 9320810
    Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: April 26, 2016
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Kimmo Porkka, Sven Christian
  • Publication number: 20160022831
    Abstract: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof.
    Type: Application
    Filed: March 22, 2015
    Publication date: January 28, 2016
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Lianglin Zhang, Jason Hoffman, Erkki Ruoslahti
  • Patent number: 9180161
    Abstract: Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: November 10, 2015
    Assignees: Sanford Burnham Prebys Medical Discovery Institute, Vascular BioSciences
    Inventors: Masanobu Komatsu, David Marshall Mann, Erkki Ruoslahti
  • Publication number: 20150259380
    Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences, such as truncated LyP-1 peptides, that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
    Type: Application
    Filed: August 24, 2012
    Publication date: September 17, 2015
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara, Lise Roth
  • Patent number: 9115170
    Abstract: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing ?v integrins.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: August 25, 2015
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Kazuki Sugahara, Tambet Teesalu
  • Patent number: 9101671
    Abstract: Disclosed are compositions and methods related to clot binding compounds. For example, disclosed are conjugates comprising a surface molecule and a plurality of clot binding compounds. The clot binding compounds can selectively bind to clotted plasma protein. The conjugate can, for example, cause clotting and amplify the accumulation of the conjugate in tumors. In one example, the conjugate can comprise a sufficient number and composition of clot binding compounds such that the conjugate causes clotting and amplifies the accumulation of the conjugate in tumors. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Grant
    Filed: December 31, 2007
    Date of Patent: August 11, 2015
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Dmitri Simberg